xvi.

2D，3D和4D软组织成像

肿瘤运动是抑制放射治疗中靶向准确性的重要因素。通过需要在治疗系统的参考框架内可视化内部结构，驱动X射线容量成像（XVI）及其成像工具套件的开发，以减少几何不确定性。在治疗位置治疗患者的治疗时图像的能力减少了与器官运动有关的问题，并激发临床信心以追求先进的交付技术。


XVI成像技术

Planning and treating in 3D requires verification in 3D. The 3D imaging capability of XVI enables clinicians to take full advantage of complex techniques without the need for implanted markers to visualize soft tissue structures, target volume and the position of critical structures.

它允许将重建的图像数据的精确登记具有历史CT计划数据作为非侵入性过程。XVI提供各种图像引导选项，以满足患者的个人需求，诊所XVI软件可灵活地改变获取VolumeView Image所需的剂量，具体取决于所需的对比度。


临床合作

Working closely with the Elekta Synergy Research Group, Elekta, in collaboration with its clinical partners, became the first company to support research on IGRT, the first to bring 3D volumetric imaging into clinical use and the first to bring these solutions to the wider market.

待遇时Volumeview成像提供的主要优点包括：

  • 可视化软组织尺寸和位置
  • Visualization of critical organs and tumors
  • Visualization of bony anatomy and alignment in 3D
  • 消除替代标记
  • Ability to reduce the imaging dose
  • Ability to overlay structures defined in treatment planning system
  • 大视场
  • 同时收购和重建

额外资源

Versa HD

Versa HD™

Versatile, all in one system from classic radiotherapy to advanced stereotactic precision.

ELEKTA最先进的线性加速器，能够为扩大的目标提供精美剂量一致性，以及旨在提高效率的地面打破创新。适用于立体定向处理技术。

了解更多

治疗解决方案


At the forefront of clinical advancements, Elekta has been instrumental in delivering techniques like IGRT, IMRT, VMAT as well as SBRT and SRT. These techniques have given clinicians the flexibility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.

了解更多